ALK ligand ALKAL2 potentiates MYCN‐driven neuroblastoma in the absence of ALK mutation

Neuroblastoma is a childhood disease that has 8-10% ALK positive and may be higher in the replapse population. Overexpression of ALKAL2 (ligand for ALK) located on chromosome 2p with neutral MYC oncogene can drive neuroblastoma in the absense of ALK mutation. READ ARTICLE

European Molecular Biology Organization (EMBO) DOI: 10.15252/embj.2020105784

Authors: Marcus Borenäs,Ganesh Umapathy,Wei-Yun Lai,Dan E Lind,Barbara Witek,Jikui Guan, Patricia Mendoza-Garcia,Tafheem Masudi,Arne Claeys,Tzu-Po Chuang,Abeer El Wakil, Badrul Arefin,Susanne Fransson,Jan Koster,Mathias Johansson,Jennie Gaarder,Jimmy Van den Eynden, Bengt Hallberg, Ruth H Palmer

Clinical TrialsKirk SmithJanuary 1, 2021ALK receptor, neuroblastoma, neural MYC, MYCN, oncogene, ALKAL2 ligand